Voyager Therapeutics, Inc. — Operating Income by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/c22b0f85-972e-4c5f-a5a9-f591baecbe61/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-131.8M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-025197 |
| FY 2024 | $-83.3M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-002703 |
| FY 2023 | $122.0M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-001988 |
| FY 2022 | $-50.8M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-002989 |
| FY 2021 | $-73.6M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-003015 |
| FY 2020 | $27.4M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-001865 |
| FY 2019 | $-51.7M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-001974 |
| FY 2018 | $-91.1M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001105 |
| FY 2017 | $-71.9M | 2017-01-01 – 2017-12-31 | evidence 0001558370-18-002038 |
| FY 2016 | $-41.3M | 2016-01-01 – 2016-12-31 | evidence 0001558370-17-001797 |
| FY 2015 | $-20.3M | 2015-01-01 – 2015-12-31 | evidence 0001558370-16-004222 |
| FY 2014 | $-14.4M | 2014-01-01 – 2014-12-31 | evidence 0001558370-16-004222 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Voyager Therapeutics, Inc. — all facts · Revenue · Net Income